ClinicalTrials.gg
CompletedNCT01376388DB2115362Updated Jan 9, 2017Results posted

Long-term Safety Study for GSK573719/GW642444 in Japanese

A Phase 3 interventional study of GSK573719/GW642444 Inhalation Powder in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 23 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-01-09.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
131
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, none of them phase 3. GSK573719 · Pulmonary Disease, Chronic Obstructive.

Enrollment
22nd of 43
131 · median 131
Started
2011
with 7 others
Phase 3
14 of 43
none open now
Registered
11th of 43
by date
Lead sponsor
35 of 43
GlaxoSmithKline

Among the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, this one is the 22nd largest by enrollment, is one of 8 that started in 2011, is one of 14 in phase 3, and was the 11th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About GSK573719

GSK573719: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and tolerability of GSK573719/GW642444 Inhalation Powder 125/25 mcg once-daily. The product will be delivered via the Novel Dry Powder Inhaler (nDPI) over 52 weeks to Japanese subjects with Chronic Obstructive Pulmonary Disease (COPD). This is a multi-centre, open-label study evaluating the safety of GSK573719/GW642444 Inhalation Powder 125/25 mcg. Treatment will be given once-daily in the morning. The target enrolment is approximately 120 subjects at approximately 20 study centres in Japan. The total duration of subject participation will be 54-55 weeks, consisting of a 7-14 day run-in period, 52-week treatment period and 1-week follow-up period. Subjects meeting all of the inclusion criteria and none of the exclusion criteria at screening visit (Visit 1) will enter 7-14 day run-in period. The run-in period is provided for completion of baseline safety evaluations and to obtain baseline measures of COPD status. At Visit 2, eligible subjects will start to take GSK573719/GW642444 125/25 mcg, and enter the treatment period. This treatment will be delivered via the Novel Dry Powder Inhaler (nDPI) once daily in the morning for 52 weeks. One nDPI will contain 30 doses of study medication. Subjects will be instructed to administer medication once daily in the morning for the duration of the 52-week treatment period. Each subject should be advised to adhere to this dosing regimen throughout the study. There will be a total of 8 study visits including at screening (Visit 1), initiation of treatment (Visit 2), and at 4weeks, 8 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks (Visit 3 through Visit 8, respectively). Follow-up (Visit 9) will be conducted by the phone contact approximately 1 week following the completion/withdrawal of treatment period. A subject will be considered to have completed the study upon completion of the last on-treatment visit (Visit 8). At the end of the treatment period, subjects will be prescribed appropriate COPD medication at the investigator's discretion.

Read the detailed description

The objective of this study is to evaluate the safety and tolerability of GSK573719/GW642444 Inhalation Powder 125/25 mcg once-daily. The product will be delivered via the Novel Dry Powder Inhaler (nDPI) over 52 weeks to Japanese subjects with Chronic Obstructive Pulmonary Disease (COPD). This is a multi-centre, open-label study evaluating the safety of GSK573719/GW642444 Inhalation Powder 125/25 mcg. Treatment will be given once-daily in the morning. The target enrolment is approximately 120 subjects at approximately 20 study centres in Japan. The total duration of subject participation will be 54-55 weeks, consisting of a 7-14 day run-in period, 52-week treatment period and 1-week follow-up period. Subjects meeting all of the inclusion criteria and none of the exclusion criteria at screening visit (Visit 1) will enter 7-14 day run-in period. The run-in period is provided for completion of baseline safety evaluations and to obtain baseline measures of COPD status. Cardiovascular medical history/risk factors will be assessed at baseline. The following information will be collected from subjects receiving study medication and recorded in the eCRF: demography (including gender, ethnic origin and date of birth, height, weight), medical history (including duration of COPD and smoking history), COPD exacerbation assessment (documented history of ≥1 COPD exacerbation that required antibiotics/systemic corticosteroids or hospitalization in the past 12 months), concurrent medical conditions, and concomitant medication. At Visit 2, eligible subjects will start to take GSK573719/GW642444 125/25 mcg, and enter the treatment period. This treatment will be delivered via the Novel Dry Powder Inhaler (nDPI) once daily in the morning for 52 weeks. One nDPI will contain 30 doses of study medication. Subjects will be instructed to administer medication once daily in the morning for the duration of the 52-week treatment period. Each subject should be advised to adhere to this dosing regimen throughout the study. There will be a total of 8 study visits including at screening (Visit 1), initiation of treatment (Visit 2), and at 4weeks, 8 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks (Visit 3 through Visit 8, respectively). Follow-up (Visit 9) will be conducted by the phone contact approximately 1 week following the completion/withdrawal of treatment period. A subject will be considered to have completed the study upon completion of the last on-treatment visit (Visit 8). At the end of the treatment period, subjects will be prescribed appropriate COPD medication at the investigator's discretion. Primary endpoint is incidence and severity of adverse events. Secondary endpoints are clinical laboratory tests (hematology, clinical chemistry), change from baseline in vital signs (pulse rate and systolic and diastolic pressure), and 12-lead Electrocardiogram (ECG) assessments. And other endpoints are change from baseline in trough Forced Expiratory Volume in One Second (FEV1) and Forced Vital Capacity (FVC), number of puffs of supplemental use of salbutamol, percentage of rescue-free days, percentage of symptom-free days, mean symptom scores, incidence of COPD exacerbations, and COPD device preference questionnaire.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Pharmacogenetics
  • GSK573719/GW642444
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatient.
  • A signed and dated written prior to study participation.
  • Japanese subjects 40 years of age or older at screening.
  • Male or female subjects (female subjects who have child bearing potential has a negative pregnancy test at screening, and agrees to one of the acceptable methods used consistently and correctly).
  • Diagnosis of .
  • 10 pack-year or greater history of cigarette smoking.
  • Post-bronchodilator /FVC of \<0.7.
  • Predicted FEV1 of \<80%.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • A current diagnosis of asthma.
  • Respiratory disorders other than .
  • non-respiratory diseases or abnormalities that are not adequate controlled.
  • A chest X-ray or computed tomography (CT) scan that reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD.
  • A history of allergy or to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition.
  • Hospitalization for COPD or pneumonia within 12 weeks prior to screening.
  • Subjects with lung volume reduction surgery within the 12 months prior to screening.
  • Abnormal and clinically significant findings at screening.
  • Significantly abnormal finding from clinical chemistry or hematology, tests at screening.
  • Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day.
  • Regular use (prescribed every day, not for as-needed use) of short-acting bronchodilators via nebulized therapy.
  • Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to screening.
  • A know or suspected history of alcohol or drug abuse within 2 years prior to screening.
  • Affiliation with the site.
  • Previous use of GSK573719, GW642444, the GSK573719/GW642444 combination or the Fluticasone Furoate/GW642444 combination.
  • Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    GSK573719/GW642444

    125/25mcg

    Drug: GSK573719/GW642444 Inhalation Powder

Interventions

  • DrugGSK573719/GW642444 Inhalation Powder

    Drug pages: GSK573719 · Vilanterol

    GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period

    An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occuring at a frequency threshold of \>=5%) and SAEs.

    Time frame: 52 weeks

  2. Number of Participants With AEs Classified by the Indicated Maximum Grade Throughout the Treatment Period

    An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. AEs were classified according to intensity based upon the investigators' clinical judgment. The intensity was categorized as: mild (an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities); moderate (an event that is sufficiently discomforting to interfere with normal everyday activities); or severe (an event that prevents normal everyday activities).

    Time frame: 52 weeks

Secondary outcomes

  1. Basophil, Eosinophil, Lymphocyte, Monocyte, and Total Neutrophil Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD

    Blood samples were collected for the measurement of the indicated laboratory parameters at following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

    Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD

  2. Eosinophil Values, Total Neutrophil Values, Platelet Count, and White Blood Cell (WBC) Count at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD

    Blood samples were collected for the measurment of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

    Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD

  3. Hemoglobin, Albumin, and Total Protein Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/Withdrawal (WD)

    Blood samples were collected for the measurement of hemoglobin, albumin, and total protein at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

    Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD

  4. Hematocrit Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD

    Blood samples were collected for the measurement of hematocrit at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

    Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD

  5. Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, and Gamma Glutamyl Transferase (GGT) Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the WD Visit, Week 24/WD, and Week 52/WD

    Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

    Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD

  6. Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine, and Uric Acid Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the WD Visit, Week 24/WD, and Week 52/WD

    Blood samples were collected for the measuremnt of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

    Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD

  7. Calcium, Chloride, Glucose, Carbon Dioxide/Bicarbonate (CO2/HCO3), Potassium, Sodium, Phosphorous Inorganic, and Urea/Blood Urea Nitrogen (Urea/BUN) Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD

    Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

    Time frame: BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD

  8. Change From Baseline in Blood Pressure

    Blood pressure measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Blood pressure was measured in a sitting position after the participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the assessment value at the time of interest minus the Baseline value. The WD visit was conducted for participants who withdrew at any point during the study. The Week 24/WD visit was conducted for participants who completed the Week 24 visit or withdrew before Week 24. The Week 52/WD visit was conducted for participants who completed the Week 52 visit or withdrew before Week 52.

    Time frame: Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD

  9. Change From Baseline in Heart Rate

    Heart rate was measured in a sitting position after the participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the assessment value at the time of interest minus the Baseline value. The WD visit was conducted for participants who withdrew at any point during the study. The Week 24/WD visit was conducted for participants who completed the Week 24 visit or withdrew before Week 24. The Week 52/WD visit was conducted for participants who completed the Week 52 visit or withdrew before Week 52.

    Time frame: Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD

  10. Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings at the Indicated Time Points

    A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes. Data are presented as clinically significant (CS) or not clinically significant (NCS) abnormal findings. An abnormal and significant ECG finding includes the presence of a QT interval corrected for heart rate (QTc interval) \>500 milliseconds (msec) or an uncorrected QT interval \>600 msec, for participants with Bundle Branch Block QTc \>530 msec based on an average QTc value of triplicate ECGs. The study investigator determined if the abnormal ECG finding was CS or NCS. The WD visit was conducted for participants who withdrew at any point during the study. The Week 24/WD and Week 52/WD visits were conducted for participants who completed the Week 24 visit or withdrew before Week 24 and completed the Week 52 visit or withdrew before Week 52, respectively. The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

    Time frame: Baseline (Screening visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD

07

Results

Posted Mar 14, 2014

Participant flow

131 participants (par.) comprised the All Subjects Enrolled Population (ASEP; all par. with records in the study database). One par. in the ASEP was withdrawn due to a Good Clinical Practice violation and was thus withdrawn from the Intent-to-Treat Population (comprised of all participants who received at least one dose of study drug; n=130).

Participant flow — Overall Study
MilestoneUMEC/VI 125/25 µg
Started130
Completed112
Not completed18
Withdrew: Adverse event13
Withdrew: Lack of efficacy2
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryNumber of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period

An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, or is an event of possible drug-induced liver injury. Refer to the general AE/SAE module for a list of AEs (occuring at a frequency threshold of \>=5%) and SAEs.

Time frame:
52 weeks
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) Throughout the Treatment Period
ParticipantsUMEC/VI 125/25 µg
Any AE113
Any SAE16
PrimaryNumber of Participants With AEs Classified by the Indicated Maximum Grade Throughout the Treatment Period

An AE is defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. AEs were classified according to intensity based upon the investigators' clinical judgment. The intensity was categorized as: mild (an event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities); moderate (an event that is sufficiently discomforting to interfere with normal everyday activities); or severe (an event that prevents normal everyday activities).

Time frame:
52 weeks
Reported as:
Number · Participants
Number of Participants With AEs Classified by the Indicated Maximum Grade Throughout the Treatment Period
ParticipantsUMEC/VI 125/25 µg
Mild83
Moderate20
Severe10
SecondaryBasophil, Eosinophil, Lymphocyte, Monocyte, and Total Neutrophil Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD

Blood samples were collected for the measurement of the indicated laboratory parameters at following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

Time frame:
BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Reported as:
Mean · Percentage of cells in blood
Basophil, Eosinophil, Lymphocyte, Monocyte, and Total Neutrophil Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD
Percentage of cells in bloodUMEC/VI 125/25 µg
Basophils, BL (Week -2), n=1300.54 ± 0.340
Basophils, Week 12, n=1270.58 ± 0.424
Basophils, Week 24, n=1220.59 ± 0.386
Basophils, Week 52, n=1120.60 ± 0.615
Basophils, WD Visit, n=100.35 ± 0.246
Basophils, Week 24/WD, n=1290.58 ± 0.382
Basophils, Week 52/WD, n=1220.58 ± 0.597
Eosinophils, BL (Week -2), n=1303.90 ± 3.752
Eosinophils, Week 12, n=1273.73 ± 3.178
Eosinophils, Week 24, n=1224.07 ± 4.694
Eosinophils, Week 52, n=1123.54 ± 2.936
Eosinophils, WD Visit, n=102.10 ± 1.662
Eosinophils, Week 24/WD, n=1293.97 ± 4.593
Eosinophils, Week 52/WD, n=1223.42 ± 2.876
Lymphocytes, BL (Week -2), n=13029.07 ± 8.471
Lymphocytes, Week 12, n=12728.48 ± 7.703
Lymphocytes, Week 24, n=12228.40 ± 8.620
Lymphocytes, Week 52, n=11228.71 ± 7.906
Lymphocytes, WD Visit, n=1021.28 ± 8.110
Lymphocytes, Week 24/WD, n=12928.12 ± 8.636
Lymphocytes, Week 52/WD, n=12228.10 ± 8.150
Monocytes, BL (Week -2), n=1306.15 ± 1.758
Monocytes, Week 12, n=1276.33 ± 1.727
Monocytes, Week 24, n=1226.27 ± 1.541
Monocytes, Week 52, n=1126.20 ± 1.827
Monocytes, WD Visit, n=107.44 ± 1.290
Monocytes, Week 24/WD, n=1296.32 ± 1.541
Monocytes, Week 52/WD, n=1226.30 ± 1.818
Total Neutrophils, BL (Week -2), n=13060.34 ± 9.047
Total Neutrophils, Week 12, n=12760.88 ± 8.880
Total Neutrophils, Week 24, n=12260.67 ± 9.595
Total Neutrophils, Week 52, n=11260.96 ± 8.714
Total Neutrophils, WD Visit, n=1068.83 ± 8.296
Total Neutrophils, Week 24/WD, n=12961.01 ± 9.538
Total Neutrophils, Week 52/WD, n=12261.60 ± 8.915
SecondaryEosinophil Values, Total Neutrophil Values, Platelet Count, and White Blood Cell (WBC) Count at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD

Blood samples were collected for the measurment of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

Time frame:
BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Reported as:
Mean · 10^9 cells/Liter (GI/L)
Eosinophil Values, Total Neutrophil Values, Platelet Count, and White Blood Cell (WBC) Count at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD
10^9 cells/Liter (GI/L)UMEC/VI 125/25 µg
Eosinophils, BL (Week -2), n=1300.245 ± 0.2324
Eosinophils, Week 12, n=1270.225 ± 0.1815
Eosinophils, Week 24, n=1220.260 ± 0.3243
Eosinophils, Week 52, n=1120.219 ± 0.1992
Eosinophils, WD Visit, n=100.135 ± 0.1031
Eosinophils, Week 24/WD, n=1290.254 ± 0.3171
Eosinophils, Week 52/WD, n=1220.212 ± 0.1942
Total Neutrophils, BL (Week -2), n=1303.874 ± 1.2587
Total Neutrophils, Week 12, n=1273.798 ± 1.2169
Total Neutrophils, Week 24, n=1223.946 ± 1.5517
Total Neutrophils, Week 52, n=1123.899 ± 1.5434
Total Neutrophils, WD Visit, n=104.860 ± 2.0869
Total Neutrophils, Week 24/WD, n=1293.953 ± 1.5326
Total Neutrophils, Week 52/WD, n=1223.978 ± 1.6060
Platelet Count, BL (Week -2), n=130234.3 ± 54.92
Platelet Count, Week 12, n=127238.6 ± 56.35
Platelet Count, Week 24, n=122239.3 ± 59.54
Platelet Count, Week 52, n=112233.8 ± 58.63
Platelet Count, WD Visit, n=10232.0 ± 84.03
Platelet Count, Week 24/WD, n=129240.0 ± 60.02
Platelet Count, Week 52/WD, n=122233.6 ± 60.65
WBC Count, BL (Week -2), n=1306.38 ± 1.588
WBC Count, Week 12, n=1276.18 ± 1.443
WBC Count, Week 24, n=1226.39 ± 1.803
WBC Count, Week 52, n=1126.30 ± 1.892
WBC Count, WD Visit, n=106.88 ± 2.203
WBC Count, Week 24/WD, n=1296.37 ± 1.778
WBC Count, Week 52/WD, n=1226.35 ± 1.916
SecondaryHemoglobin, Albumin, and Total Protein Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/Withdrawal (WD)

Blood samples were collected for the measurement of hemoglobin, albumin, and total protein at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

Time frame:
BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Reported as:
Mean · Grams/Liter (G/L)
Hemoglobin, Albumin, and Total Protein Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/Withdrawal (WD)
Grams/Liter (G/L)UMEC/VI 125/25 µg
Hemoglobin, BL (Week -2), n=130145.1 ± 13.35
Hemoglobin, Week 12, n=127148.2 ± 13.02
Hemoglobin, Week 24, n=122148.1 ± 13.58
Hemoglobin, Week 52, n=112148.2 ± 14.02
Hemoblobin, WD Visit, n=10146.6 ± 12.82
Hemoglobin, Week 24/WD, n=129148.0 ± 13.53
Hemoglobin, Week 52/WD, n=122148.0 ± 13.88
Albumin, BL (Week -2), n=13042.5 ± 2.58
Albumin, Week 12, n=12742.9 ± 2.44
Albumin, Week 24, n=12242.4 ± 2.76
Albumin, Week 52, n=11241.9 ± 2.96
Albumin, WD Visit, n=1041.3 ± 3.68
Albumin, Week 24/WD, n=12942.3 ± 2.80
Albumin, Week 52/WD, n=12241.9 ± 3.01
Total Protein, BL (Week -2), n=13070.9 ± 4.20
Total Protein, Week 12, n=12771.8 ± 4.50
Total Protein, Week 24, n=12271.2 ± 4.20
Total Protein, Week 52, n=11270.8 ± 4.78
Total Protein, WD Visit, n=1068.7 ± 5.46
Total Protein, Week 24/WD, n=12971.0 ± 4.22
Total Protein, Week 52/WD, n=12270.6 ± 4.85
SecondaryHematocrit Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD

Blood samples were collected for the measurement of hematocrit at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

Time frame:
BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Reported as:
Mean · Proportion
Hematocrit Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the Withdrawal (WD) Visit, Week 24/WD, and Week 52/WD
ProportionUMEC/VI 125/25 µg
BL (Week -2), n=1300.4460 ± 0.03857
Week 12, n=1270.4534 ± 0.03575
Week 24, n=1220.4515 ± 0.03720
Week 52, n=1120.4517 ± 0.04063
WD Visit, n=100.4473 ± 0.03970
Week 24/WD, n=1290.4512 ± 0.03724
Week 52/WD, n=1220.4513 ± 0.04041
SecondaryAlkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, and Gamma Glutamyl Transferase (GGT) Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the WD Visit, Week 24/WD, and Week 52/WD

Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

Time frame:
BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Reported as:
Mean · International Units/Liter (IU/L)
Alkaline Phosphatase (AP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase, and Gamma Glutamyl Transferase (GGT) Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the WD Visit, Week 24/WD, and Week 52/WD
International Units/Liter (IU/L)UMEC/VI 125/25 µg
AP, BL (Week -2), n=130242.1 ± 80.70
AP, Week 12, n=127250.2 ± 82.01
AP, Week 24, n=122257.3 ± 81.40
AP, Week 52, n=112247.5 ± 77.43
AP, WD Visit, n=10227.7 ± 74.24
AP, Week 24/WD, n=129254.2 ± 80.75
AP, Week 52/WD, n=122245.9 ± 77.07
ALT, BL (Week -2), n=13020.0 ± 10.42
ALT, Week 12, n=12721.9 ± 13.19
ALT, Week 24, n=12220.8 ± 13.06
ALT, Week 52, n=11221.2 ± 12.09
ALT, WD Visit, n=1031.7 ± 28.79
ALT, Week 24/WD, n=12921.1 ± 13.56
ALT, Week 52/WD, n=12222.0 ± 14.29
AST, BL (Week -2), n=13023.4 ± 7.35
AST, Week 12, n=12725.0 ± 8.90
AST, Week 24, n=12223.9 ± 9.62
AST, Week 52, n=11224.3 ± 8.94
AST, WD Visit, n=1041.1 ± 42.05
AST, Week 24/WD, n=12924.7 ± 14.48
AST, Week 52/WD, n=12225.7 ± 15.04
Creatine Kinase, BL (Week -2), n=130114.1 ± 59.56
Creatine Kinase, Week 12, n=127120.3 ± 111.89
Creatine Kinase, Week 24, n=122100.8 ± 42.60
Creatine Kinase, Week 52, n=112111.3 ± 59.60
Creatine Kinase, WD Visit, n=10387.5 ± 971.63
Creatine Kinase, Week 24/WD, n=129124.0 ± 271.90
Creatine Kinase, Week 52/WD, n=122134.0 ± 281.54
GGT, BL (Week -2), n=13047.1 ± 54.80
GGT, Week 12, n=12749.1 ± 57.91
GGT, Week 24, n=12249.1 ± 63.21
GGT, Week 52, n=11253.9 ± 78.30
GGT, WD Visit, n=1046.3 ± 26.29
GGT, Week 24/WD Visit, n=12949.2 ± 61.82
GGT, Week 52/WD Visit, n=12253.3 ± 75.37
SecondaryDirect Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine, and Uric Acid Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the WD Visit, Week 24/WD, and Week 52/WD

Blood samples were collected for the measuremnt of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

Time frame:
BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Reported as:
Mean · Micromoles/Liter (µM/L)
Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine, and Uric Acid Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, the WD Visit, Week 24/WD, and Week 52/WD
Micromoles/Liter (µM/L)UMEC/VI 125/25 µg
Direct Bilirubin, BL (Week -2), n=1303.736 ± 1.7659
Direct Bilirubin, Week 12, n=1273.514 ± 1.6731
Direct Bilirubin, Week 24, n=1223.350 ± 1.4975
Direct Bilirubin, Week 52, n=1123.680 ± 1.6426
Direct Bilirubin, WD Visit, n=103.249 ± 0.5407
Direct Bilirubin, Week 24/WD, n=1293.340 ± 1.4632
Direct Bilirubin, Week 52/WD, n=1223.644 ± 1.5846
Indirect Bilirubin, BL (Week -2), n=1307.064 ± 2.8991
Indirect Bilirubin, Week 12, n=1276.975 ± 2.7725
Indirect Bilirubin, Week 24, n=1226.728 ± 2.5424
Indirect Bilirubin, Week 52, n=1127.008 ± 2.9302
Indirect Bilirubin, WD Visit, n=105.985 ± 2.4517
Indirect Bilirubin, Week 24/WD, n=1296.641 ± 2.5348
Indirect Bilirubin, Week 52/WD, n=1226.924 ± 2.8987
Total Bilirubin, BL (Week -2), n=13010.799 ± 4.3585
Total Bilirubin, Week 12, n=12710.489 ± 4.1067
Total Bilirubin, Week 24, n=12210.078 ± 3.6643
Total Bilirubin, Week 52, n=11210.687 ± 4.2603
Total Bilirubin, WD Visit, n=109.234 ± 2.8156
Total Bilirubin, Week 24/WD, n=1299.982 ± 3.6261
Total Bilirubin, Week 52/WD, n=12210.568 ± 4.1714
Creatinine, BL (Week -2), n=13074.3036 ± 19.60971
Creatinine, Week 12, n=12774.3047 ± 19.32910
Creatinine, Week 24, n=12273.2633 ± 18.90496
Creatinine, Week 52, n=11275.6609 ± 18.69402
Creatinine, WD Visit, n=1071.8692 ± 10.60022
Creatinine, Week 24/WD, n=12973.2692 ± 18.55960
Creatinine, Week 52/WD, n=12275.3501 ± 18.16682
Uric Acid, BL (Week -2), n=130357.8408 ± 81.73895
Uric Acid, Week 12, n=127353.2737 ± 81.17581
Uric Acid, Week 24, n=122348.2993 ± 80.93244
Uric Acid, Week 52, n=112353.2687 ± 89.55111
Uric Acid, WD Visit, n=10343.7944 ± 87.40840
Uric Acid, Week 24/WD, n=129349.1799 ± 80.95415
Uric Acid, Week 52, n=122352.4921 ± 89.06027
SecondaryCalcium, Chloride, Glucose, Carbon Dioxide/Bicarbonate (CO2/HCO3), Potassium, Sodium, Phosphorous Inorganic, and Urea/Blood Urea Nitrogen (Urea/BUN) Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD

Blood samples were collected for the measurement of the indicated laboratory parameters at the following time points: BL (Week -2), Week 12, Week 24, Week 52, WD Visit (conducted for participants who withdrew at any point during the study), Week 24/WD (conducted for participants who completed the Week 24 visit or withdrew before Week 24), and Week 52/WD (conducted for participants who completed the Week 52 visit or withdrew before Week 52). The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

Time frame:
BL (Screening visit: Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Reported as:
Mean · Millimoles/Liter (MMOL/L)
Calcium, Chloride, Glucose, Carbon Dioxide/Bicarbonate (CO2/HCO3), Potassium, Sodium, Phosphorous Inorganic, and Urea/Blood Urea Nitrogen (Urea/BUN) Values at Baseline (BL; Week -2), Week 12, Week 24, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Millimoles/Liter (MMOL/L)UMEC/VI 125/25 µg
Calcium, BL (Week -2), n=1302.2954 ± 0.09315
Calcium, Week 12, n=1272.2948 ± 0.09903
Calcium, Week 24, n=1222.2837 ± 0.09096
Calcium, Week 52, n=1122.2765 ± 0.09993
Calcium, WD Visit, n=102.2829 ± 0.15878
Calcium, Week 24/WD, n=1292.2842 ± 0.09439
Calcium, Week 52/WD, n=1222.2770 ± 0.10506
Chloride, BL (Week -2), n=130103.7 ± 2.65
Chloride, Week 12, n=127105.7 ± 2.51
Chloride, Week 24, n=122105.7 ± 2.70
Chloride, Week 52, n=112105.5 ± 2.93
Chloride, WD Visit, n=10104.2 ± 3.65
Chloride, Week 24/WD, n=129105.6 ± 2.79
Chloride, Week 52/WD, n=122105.4 ± 3.00
Glucose, BL (Week -2), n=1306.4447 ± 1.86640
Glucose, Week 12, n=1276.3343 ± 1.63238
Glucose, Week 24, n=1226.7313 ± 2.20449
Glucose, Week 52, n=1126.6325 ± 1.81891
Glucose, WD Visit, n=106.5280 ± 1.52070
Glucose, Week 24/WD, n=1296.7085 ± 2.15445
Glucose, Week 52/WD, n=1226.6239 ± 1.79105
CO2/HCO3, BL (Week -2), n=13025.7 ± 2.32
CO2/HCO3, Week 12, n=12725.1 ± 2.29
CO2/HCO3, Week 24, n=12224.1 ± 2.31
CO2/HCO3, Week 52, n=11223.8 ± 2.18
CO2/HCO3, WD Visit, n=1024.3 ± 3.50
CO2/HCO3, Week 24/WD, n=12924.2 ± 2.41
CO2/HCO3, Week 52/WD, n=12223.9 ± 2.30
Potassium, BL (Week -2), n=1304.29 ± 0.380
Potassium, Week 12, n=1274.34 ± 0.384
Potassium, Week 24, n=1224.33 ± 0.374
Potassium, Week 52, n=1124.31 ± 0.362
Potassium, WD Visit, n=104.42 ± 0.301
Potassium, Week 24/WD, n=1294.33 ± 0.366
Potassium, Week 52/WD, n=1224.32 ± 0.357
Sodium, BL (Week -2), n=130141.4 ± 2.09
Sodium, Week 12, n=127142.3 ± 1.95
Sodium, Week 24, n=122142.3 ± 2.03
Sodium, Week 52, n=112141.4 ± 2.26
Sodium, WD Visit, n=10140.4 ± 3.72
Sodium, Week 24/WD, n=129142.2 ± 2.21
Sodium, Week 52/WD, n=122141.4 ± 2.41
Phosphorous Inorganic, BL (Week -2), n=1300.9714 ± 0.15901
Phosphorous Inorganic, Week 12, n=1271.0124 ± 0.16447
Phosphorous Inorganic, Week 24, n=1220.9975 ± 0.16216
Phosphorous Inorganic, Week 52, n=1120.9448 ± 0.16492
Phosphorous Inorganic, WD Visit, n=100.9913 ± 0.17558
Phosphorous Inorganic, Week 24/WD, n=1290.9985 ± 0.16349
Urea/BUN, BL (Week -2), n=1300.9486 ± 0.16555
Phosphorous Inorganic, Week 52/WD, n=1225.2660 ± 1.52578
Urea/BUN, Week 12, n=1275.4764 ± 1.80029
Urea/BUN, Week 24, n=1225.4998 ± 1.50802
Urea/BUN, Week 52, n=1125.4570 ± 1.66582
Urea/BUN, WD Visit, n=105.4335 ± 2.05521
Urea/BUN, Week 24/WD, n=1295.4856 ± 1.52903
Urea/BUN, Week 52/WD, n=1225.4551 ± 1.69111
SecondaryChange From Baseline in Blood Pressure

Blood pressure measurements included systolic blood pressure (SBP) and diastolic blood pressure (DBP). Blood pressure was measured in a sitting position after the participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the assessment value at the time of interest minus the Baseline value. The WD visit was conducted for participants who withdrew at any point during the study. The Week 24/WD visit was conducted for participants who completed the Week 24 visit or withdrew before Week 24. The Week 52/WD visit was conducted for participants who completed the Week 52 visit or withdrew before Week 52.

Time frame:
Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Reported as:
Mean · Millimeters of Mercury (mmHg)
Change From Baseline in Blood Pressure
Millimeters of Mercury (mmHg)UMEC/VI 125/25 µg
SBP, Week 4, n=1281.1 ± 12.27
SBP, Week 8, n=1272.0 ± 13.79
SBP, Week 12, n=1272.5 ± 13.62
SBP, Week 24, n=1222.7 ± 14.80
SBP, Week 36, n=116-3.3 ± 13.80
SBP, Week 52, n=1120.4 ± 13.82
SBP, WD Visit, n=10-2.3 ± 18.62
SBP, Week 24/WD, n=1292.5 ± 15.09
SBP, Week 52/WD, n=1220.2 ± 14.19
DBP, Week 4, n=1281.0 ± 9.21
DBP, Week 8, n=1271.4 ± 9.99
DBP, Week 12, n=1270.9 ± 10.71
DBP, Week 24, n=1220.9 ± 10.81
DBP, Week 36, n=116-1.5 ± 11.10
DBP, Week 52, n=1120.6 ± 10.23
DBP, WD Visit, n=10-2.0 ± 11.05
DBP, Week 24/WD, n=1290.6 ± 10.92
DBP, Week 52/WD, n=1220.4 ± 10.28
SecondaryChange From Baseline in Heart Rate

Heart rate was measured in a sitting position after the participant was kept at rest for at least 5 minutes. Change from Baseline was calculated as the assessment value at the time of interest minus the Baseline value. The WD visit was conducted for participants who withdrew at any point during the study. The Week 24/WD visit was conducted for participants who completed the Week 24 visit or withdrew before Week 24. The Week 52/WD visit was conducted for participants who completed the Week 52 visit or withdrew before Week 52.

Time frame:
Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Reported as:
Mean · Beats per minute
Change From Baseline in Heart Rate
Beats per minuteUMEC/VI 125/25 µg
Week 4, n=128-0.7 ± 10.21
Week 8, n=127-0.7 ± 9.39
Week 12, n=127-1.4 ± 10.81
Week 24, n=122-0.5 ± 10.63
Week 36, n=116-2.2 ± 10.56
Week 52, n=112-0.7 ± 10.63
WD Visit, n=109.0 ± 10.46
Week 24/WD, n=129-0.1 ± 10.67
Week 52/WD, n=1220.1 ± 10.90
SecondaryNumber of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings at the Indicated Time Points

A 12-lead ECG was recorded in a supine position after the participant was kept at rest in this position for at least 5 minutes. Data are presented as clinically significant (CS) or not clinically significant (NCS) abnormal findings. An abnormal and significant ECG finding includes the presence of a QT interval corrected for heart rate (QTc interval) \>500 milliseconds (msec) or an uncorrected QT interval \>600 msec, for participants with Bundle Branch Block QTc \>530 msec based on an average QTc value of triplicate ECGs. The study investigator determined if the abnormal ECG finding was CS or NCS. The WD visit was conducted for participants who withdrew at any point during the study. The Week 24/WD and Week 52/WD visits were conducted for participants who completed the Week 24 visit or withdrew before Week 24 and completed the Week 52 visit or withdrew before Week 52, respectively. The Baseline value for clinical laboratory tests was the value recorded on Week -2 (Screening visit).

Time frame:
Baseline (Screening visit: Week -2), Week 12, Week 24, Week 36, Week 52, WD Visit, Week 24/WD, and Week 52/WD
Reported as:
Number · Participants
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings at the Indicated Time Points
ParticipantsUMEC/VI 125/25 µg
BL (Week -2), Abnormal NCS, n=13045
BL (Week -2), Abnormal CS, n=1302
Week 12, Abnormal NCS, n=12750
Week 12, Abnormal CS, n=1272
Week 24, Abnormal NCS, n=12243
Week 24, Abnormal CS, n=1223
Week 36, Abnormal NCS, n=11645
Week 36, Abnormal CS, n=1162
Week 52, Abnormal NCS, n=11247
Week 52, Abnormal CS, n=1122
WD Visit, Abnormal NCS, n=94
WD Visit, Abnormal CS, n=90
Week 24/WD, Abnormal NCS, n=12846
Week 24/WD, Abnormal CS, n=1283
Week 52/WD, Abnormal NCS, n=12151
Week 52/WD, Abnormal CS, n=1212

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication until Follow-up (up to 53 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK573719/GW642444—16/130 (12.3%)70/130 (53.8%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventGSK573719/GW642444
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders5/130
PneumoniaInfections and infestations3/130
PneumothoraxRespiratory, thoracic and mediastinal disorders1/130
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders1/130
NasopharyngitisInfections and infestations1/130
Pneumonia bacterialInfections and infestations1/130
DysphagiaGastrointestinal disorders1/130
Inguinal herniaGastrointestinal disorders1/130
Radicular cystGastrointestinal disorders1/130
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/130
Most frequent other events
Most frequent other events
EventGSK573719/GW642444
NasopharyngitisInfections and infestations49/130
BronchitisInfections and infestations13/130
PharyngitisInfections and infestations9/130
ConstipationGastrointestinal disorders7/130

Baseline characteristics

Age, Continuous
Age, Continuous(Years)UMEC/VI 125/25 µg
Mean70.4 ± 7.86
Gender
Gender(Participants)UMEC/VI 125/25 µg
Female10
Male120
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)UMEC/VI 125/25 µg
Asian - Japanese Heritage130
08

Study locations

23 sites
  • GSK Investigational Site
    Fukuoka, 802-0083, Japan
  • GSK Investigational Site
    Gunma, 371-0048, Japan
  • GSK Investigational Site
    Hiroshima, 732-0052, Japan
  • GSK Investigational Site
    Hiroshima, 732-0057, Japan
  • GSK Investigational Site
    Hokkaido, 064-0915, Japan
  • GSK Investigational Site
    Hokkaido, 080-0805, Japan
  • GSK Investigational Site
    Hyogo, 665-0827, Japan
  • GSK Investigational Site
    Hyogo, 670-0849, Japan
  • GSK Investigational Site
    Ibaraki, 300-0053, Japan
  • GSK Investigational Site
    Kagawa, 763-8502, Japan
  • GSK Investigational Site
    Kanagawa, 239-0821, Japan
  • GSK Investigational Site
    Kyoto, 615-8087, Japan
  • GSK Investigational Site
    Oita, 870-0921, Japan
  • GSK Investigational Site
    Oita, 876-0047, Japan
  • GSK Investigational Site
    Osaka, 576-0016, Japan
  • GSK Investigational Site
    Osaka, 589-0022, Japan
  • GSK Investigational Site
    Osaka, 590-0064, Japan
  • GSK Investigational Site
    Shizuoka, 436-0022, Japan
  • GSK Investigational Site
    Tokyo, 105-0004, Japan
  • GSK Investigational Site
    Tokyo, 185-0014, Japan
  • GSK Investigational Site
    Tokyo, 187-0024, Japan
  • GSK Investigational Site
    Wakayama, 641-8510, Japan
  • GSK Investigational Site
    Yamanashi, 400-0031, Japan
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2011
First posted
Jun 20, 2011
Start
Aug 2011
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Mar 14, 2014
Last update
Jan 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01376388
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 20, 2011
Start date
Aug 2011
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Mar 14, 2014
Last update
Jan 9, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GSK573719 · Vilanterol

Start the discussion